Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
(TSX-V:RKV),(Boerse Frankfurt – Freiverkehr:7JO0), VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist […]